Medincell S.A (MEDCL) | Financial Analysis & Statements
Medincell S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
74.6M
Total Liabilities
105.2M
Shareholders Equity
-30.6M
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Medincell S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 25.5M | 9.2M | 9.9M | 4.1M | 8.2M |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 25.5M | 9.2M | 9.9M | 4.1M | 8.2M |
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 24.3M | 21.1M | 27.9M | 23.6M | 19.5M |
| Selling, General & Administrative | 529.0K | 557.0K | 629.0K | - | - |
| Other Operating Expenses | 3.8M | 3.7M | 2.7M | 2.8M | 2.5M |
| Total Operating Expenses | 28.7M | 25.3M | 31.3M | 26.4M | 22.0M |
| Operating Income | -10.8M | -21.0M | -24.0M | -23.8M | -15.6M |
| Operating Margin % | -42.4% | -229.0% | -241.8% | -582.3% | -190.3% |
| Non-Operating Items | |||||
| Interest Income | 0 | 9.0K | 1.0K | 0 | 23.0K |
| Interest Expense | 5.1M | 4.6M | 3.9M | 1.8M | 2.3M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -18.3M | -25.0M | -32.0M | -24.8M | -19.0M |
| Income Tax | 160.0K | 88.0K | 0 | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -18.4M | -25.0M | -32.0M | -24.8M | -19.0M |
| Net Margin % | -72.2% | -273.3% | -321.9% | -606.5% | -231.9% |
| Key Metrics | |||||
| EBITDA | -11.2M | -18.6M | -26.4M | -21.4M | -15.7M |
| EPS (Basic) | €-0.62 | €-0.86 | €-1.27 | €-1.00 | €-0.86 |
| EPS (Diluted) | €-0.62 | €-0.86 | €-1.27 | €-1.00 | €-0.86 |
| Basic Shares Outstanding | 29635179 | 29071067 | 25188499 | 24865403 | 22044349 |
| Diluted Shares Outstanding | 29635179 | 29071067 | 25188499 | 24865403 | 22044349 |
Income Statement Trend
Medincell S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 59.0M | 19.5M | 6.5M | 24.6M | 47.1M |
| Short-term Investments | 12.9M | - | 3.0K | 2.0M | 2.8M |
| Accounts Receivable | 1.4M | 1.5M | 2.1M | 799.0K | 883.0K |
| Inventory | - | - | 0 | 0 | 0 |
| Other Current Assets | 100.0K | - | 55.0K | 22.0K | 16.0K |
| Total Current Assets | 80.6M | 27.3M | 19.6M | 34.1M | 56.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 7.8M | 7.2M | 4.4M | 6.9M | 4.0M |
| Goodwill | 2.6M | 2.5M | 1.9M | 1.7M | 1.5M |
| Intangible Assets | 2.6M | 2.5M | 1.9M | 1.7M | 1.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 31.0K | 13.0K | 26.0K | 42.0K | 3.0K |
| Total Non-Current Assets | 9.8M | 9.7M | 9.8M | 10.2M | 7.3M |
| Total Assets | 90.5M | 36.9M | 29.3M | 44.3M | 63.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.0M | 1.8M | 4.2M | 3.0M | 3.0M |
| Short-term Debt | 7.3M | 6.2M | 40.4M | 28.3M | 3.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 134.0K | 129.0K | 126.0K | 107.0K | 165.0K |
| Total Current Liabilities | 29.9M | 16.5M | 57.0M | 38.2M | 13.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 51.5M | 52.8M | 14.3M | 19.1M | 39.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 13.7M | 494.0K | 2.0K | 2.0K | 4.0K |
| Total Non-Current Liabilities | 76.9M | 61.3M | 14.6M | 19.4M | 40.9M |
| Total Liabilities | 106.8M | 77.8M | 71.6M | 57.7M | 54.5M |
| Equity | |||||
| Common Stock | 331.0K | 291.0K | 253.0K | 251.0K | 247.0K |
| Retained Earnings | -18.4M | -25.0M | -32.0M | -24.8M | -19.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -16.4M | -40.8M | -42.3M | -13.4M | 9.1M |
| Key Metrics | |||||
| Total Debt | 58.8M | 59.0M | 54.7M | 47.5M | 43.3M |
| Working Capital | 50.7M | 10.8M | -37.5M | -4.2M | 42.7M |
Balance Sheet Composition
Medincell S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -18.4M | -25.0M | -32.0M | -24.8M | -19.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 3.0M | 2.8M | 2.3M | 2.4M | 1.6M |
| Working Capital Changes | 22.4M | 5.5M | -4.2M | -2.4M | 804.0K |
| Operating Cash Flow | 14.1M | -12.6M | -24.9M | -23.0M | -13.4M |
| Investing Activities | |||||
| Capital Expenditures | -747.0K | -323.0K | -528.0K | -1.6M | -645.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -747.0K | -323.0K | -528.0K | -1.6M | -645.0K |
| Financing Activities | |||||
| Share Repurchases | - | -25.0K | - | -192.0K | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 13.8M | 30.0M | 3.3M | 18.7M |
| Debt Repayment | -4.1M | -8.8M | -24.1M | -2.3M | -9.3M |
| Financing Cash Flow | 35.7M | 28.4M | 6.6M | 857.0K | 51.7M |
| Free Cash Flow | 17.8M | -13.1M | -22.0M | -23.3M | -13.0M |
| Net Change in Cash | 49.1M | 15.4M | -18.8M | -23.7M | 37.7M |
Cash Flow Trend
Medincell S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-37.35
Forward P/E
96.66
Price to Sales
26.03
PEG Ratio
96.66
Profitability Ratios
Profit Margin
-61.49%
Operating Margin
-46.74%
Return on Equity
112.65%
Return on Assets
-9.16%
Financial Health
Current Ratio
2.88
Debt to Equity
-2.40
Beta
0.98
Per Share Data
EPS (TTM)
€-0.61
Book Value per Share
€-0.93
Revenue per Share
€1.03
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MEDCL | 831.6M | -37.35 | - | 112.65% | -61.49% | -2.40 |
| Abivax SA | 7.6B | -19.88 | 16.56 | -135.58% | 0.00% | 7.05 |
| Nanobiotix | 1.4B | - | - | 28.36% | -73.52% | -1.13 |
| BNP Paribas Easy | 527.3M | 22.65 | - | -96.39% | -27.22% | 2.22 |
| Valneva SE | 416.1M | 70.64 | 3.91 | -80.16% | -65.95% | 195.21 |
Financial data is updated regularly. All figures are in the company's reporting currency.